GO Therapeutics

About:

A new generation of cancer immunotherapy promise to change the paradigm of cancer treatment.

Website: http://www.gotherapeutics.com/

Top Investors: Shenzhen Salubris Pharmaceuticals

Description:

GO Therapeutics is the only company with the technologies, platforms and know-how to harness the power of the cancer glycoproteome to generate exceptionally tumor-specific antibodies for cancer immunotherapies. By making antibodies to hybrid antigens combining a tumor’s up-regulated protein expression with a protein’s aberrant glycosylation pattern, we are able to dramatically increase tumor specificity. Our technology clears the hurdles for making drugs that are extremely specific to the cancer cell.

Total Funding Amount:

$5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2014-01-01

Contact Email:

info(AT)gotherapeutics.com

Founders:

Constantine Theodoropulos, Henrik Clausen

Number of Employees:

1-10

Last Funding Date:

2017-08-17

IPO Status:

Private

Industries:

© 2025 bioDAO.ai